Search Results

FILTER BY

1 - 10 of 10 matches

Sort by:

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy

March 11, 2024

Top Heart Failure News of 2023

January 5, 2024

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

NewsConference NewsESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 8, 2021

NewsConference NewsACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

PresentationACC 2021

Benefits of SGLT1/2 Inhibition with Sotagliflozin in Heart Failure With Preserved Ejection Fraction

Presenter:

Deepak L. Bhatt

May 17, 2021

NewsConference NewsAHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 7, 2020

Advertisement

Advertisement

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.